Crenolanib (CP-868596)
Product Quick Detail
- Place Of Origin
- China
- Minimum Order
- 10
- Packaging
- vial
- Delivery
- 15 Days
Specifications
Product Name: Crenolanib (CP-868596)
Synonyms:
Crenolanib;[1-[2-[5-(3-Methyloxetan-3-ylMethoxy)benziMidazol-1-yl]quinolin-8-yl]piperidin-4-yl]aMine;1-[2-[5-[(3-Methyl-3-oxetanyl)Methoxy]-1H-benziMidazol-1-yl]-8-quinolinyl]-4-piperidinaMine;ARO
002;CP 868596;Crenolanib (CP-868569);Crenolanib (CP-868596);CP868569/Crenolanib
CAS: 670220-88-9
MF: C26H29N5O2
MW: 443.54076
Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors
density 1.36
Usage Crenolanib (CP-868569) is a highly selective and potent PDGFR-α inhibitor with IC50 of 0.9 and 1.8 nM against PDGFRα and PDGFRβ, respectively.
Usage Crenolanib (CP-868569) is a tyrosine kinase inhibitor that acts by specifically inhibiting the receptor tyrosine kinases PDGFRα and PDGFRβ. Crenolanib (CP-868569) inhibits the activity of
PDGFRα D842V kinase and prevented the phosphorylation of wild type PDGFRα. Crenolanib (CP-868569) possesses potential antineoplastic activity. Crenolanib is believed to suppress PDGFR-related
signal transduction pathways leading to the inhibition of tumor angiogenesis and tumor cell proliferation.
- Country:
- Business Type:
- Market:
- Founded Year:
- Address:
- Contact:Jackson Van
Other products from Yuancheng Group
Relate products of Crenolanib (CP-868596)
Crenolanib (CP-868596)
Product Name: Crenolanib (CP-868596) Synonyms: Crenolanib;[1-[2-[5-(3-Methyloxetan-3-ylMethoxy)benziMidazol-1-yl]quinolin-8-yl]piperidin-4-yl]aMine;1-[2-[5-[(3-Methyl-3-oxetanyl)Methoxy]-1H-benziMidazol-1-yl]-8-quinolinyl]-4-piperidinaMine;ARO 002;CP 868596;Crenolanib ...
Crenolanib (CP-868596)
Crenolanib is significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant PDGFRα kinases (D842I, D842V, D842Y, D1842-843IM, and deletion I843). Crenolanib is 135-fold more otent than imatinib against D842V in the isogenic model system, with ...
